ArticleInternational journal of laboratory hematology2026
Clinical Validation of the MC-80 Digital Morphology Analyzer in Leukocyte Classification: A Large-Scale Comparison With Manual Microscopy.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionAlthough AI-powered digital morphology analyzers are widely used for leukocyte classification, their reliability in detecting clinically significant abnormal cells requires rigorous validation. We evaluated the Mindray MC-80 system by comparing its results with those of conventional hematology analyzers and manual microscopy to assess accuracy, sensitivity, and diagnostic limitations.
methodsWe analyzed 1188 routine blood samples (881 normal, 307 abnormal). Preclassification results from the MC-80 were compared with hematology analyzer results for normal samples and with manual microscopy by senior morphologists for abnormal samples. Inter-method agreement was assessed by Passing-Bablok regression, and sensitivity and specificity were calculated using expert-reviewed findings as the reference standard.
resultsThe MC-80 preclassification demonstrated excellent correlation with reference assays, with r values greater than 0.9 for the majority of leukocyte subsets. Overall specificity reached over 99% for all cell populations. Excluding blasts and reactive lymphocytes, the sensitivity for all remaining cell types was higher than 90%. For clinically critical abnormal cells, the system attained 75% sensitivity for plasma cells (≥ 1%) and over 90% for the other five abnormal cell groups. Its specificity was above 90% for all abnormal cells except blasts, which had a specificity of 86.73%. Expert review further increased the correlation coefficients by 0.31% to 5.71%.
conclusionThe MC-80 provides robust performance for routine leukocyte classification, with a screening capability for most abnormal cells comparable to that of manual microscopy. However, its reduced sensitivity for reactive lymphocytes, blasts, and plasma cells indicates that it cannot fully replace manual review. Targeted optimization is therefore warranted before full integration into diagnostic workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.